Fiera Capital Corp Purchases Shares of 23,500 Simulations Plus, Inc. (NASDAQ:SLP)

Fiera Capital Corp purchased a new stake in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 23,500 shares of the technology company's stock, valued at approximately $576,000. Fiera Capital Corp owned approximately 0.12% of Simulations Plus at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SLP. Rice Hall James & Associates LLC increased its stake in shares of Simulations Plus by 15.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 106,082 shares of the technology company's stock valued at $2,601,000 after purchasing an additional 14,582 shares in the last quarter. GAMMA Investing LLC grew its holdings in Simulations Plus by 20,727.1% in the first quarter. GAMMA Investing LLC now owns 17,703 shares of the technology company's stock valued at $434,000 after purchasing an additional 17,618 shares during the period. North Star Investment Management Corp. purchased a new stake in shares of Simulations Plus in the first quarter valued at approximately $1,300,000. D. E. Shaw & Co. Inc. increased its holdings in Simulations Plus by 100.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 53,332 shares of the technology company's stock worth $1,487,000 after acquiring an additional 26,661 shares in the last quarter. Finally, Stephens Inc. AR increased its holdings in Simulations Plus by 191.1% in the 1st quarter. Stephens Inc. AR now owns 94,439 shares of the technology company's stock worth $2,316,000 after acquiring an additional 61,992 shares in the last quarter. 78.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on SLP. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a report on Tuesday, July 15th. KeyCorp cut Simulations Plus from an "overweight" rating to a "sector weight" rating in a report on Tuesday, July 15th. Craig Hallum reduced their target price on Simulations Plus from $45.00 to $36.00 and set a "buy" rating for the company in a report on Friday, June 13th. Stephens decreased their target price on Simulations Plus from $28.00 to $20.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Finally, JMP Securities reiterated a "market perform" rating on shares of Simulations Plus in a research report on Wednesday, June 18th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Simulations Plus presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.50.

Simulations Plus Stock Performance

Shares of SLP stock traded down $0.22 during trading hours on Friday, reaching $12.80. The company had a trading volume of 548,948 shares, compared to its average volume of 438,891. Simulations Plus, Inc. has a 12-month low of $12.39 and a 12-month high of $38.84. The company has a market capitalization of $257.66 million, a price-to-earnings ratio of -4.06 and a beta of 0.83. The stock has a fifty day moving average of $19.83 and a 200-day moving average of $26.91.

Simulations Plus (NASDAQ:SLP - Get Free Report) last issued its earnings results on Monday, July 14th. The technology company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.19. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%. The company had revenue of $20.36 million during the quarter, compared to analysts' expectations of $22.83 million. During the same period in the prior year, the business earned $0.27 EPS. The firm's quarterly revenue was up 9.8% on a year-over-year basis. On average, analysts forecast that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.